Trends in Tissue Engineering for Blood Vessels
Review article, 2012

Over the years, cardiovascular diseases continue to increase and affect not only human health but also the economic stability worldwide. The advancement in tissue engineering is contributing a lot in dealing with this immediate need of alleviating human health. Blood vessel diseases are considered as major cardiovascular health problems. Although blood vessel transplantation is the most convenient treatment, it has been delimited due to scarcity of donors and the patient's conditions. However, tissue-engineered blood vessels are promising alternatives as mode of treatment for blood vessel defects. The purpose of this paper is to show the importance of the advancement on biofabrication technology for treatment of soft tissue defects particularly for vascular tissues. This will also provide an overview and update on the current status of tissue reconstruction especially from autologous stem cells, scaffolds, and scaffold-free cellular transplantable constructs. The discussion of this paper will be focused on the historical view of cardiovascular tissue engineering and stem cell biology. The representative studies featured in this paper are limited within the last decade in order to trace the trend and evolution of techniques for blood vessel tissue engineering.

mesenchymal stem-cells

acute

smooth-muscle-cells

myocardial-infarction

stromal cells

differentiation

angiogenic efficacy

vascular grafts

endothelial progenitor cells

in-vitro

biodegradable scaffolds

Author

J. G. Nemeno-Guanzon

Konkuk University

SangWook Lee

Konkuk University

Johan Robert Berg

Chalmers, Chemical and Biological Engineering, Physical Chemistry

Y. H. Jo

Konkuk University

J. E. Yeo

Incheon Sarang Hospital

Konkuk University

B. M. Nam

Konkuk University

Y. G. Koh

Incheon Sarang Hospital

J. I. Lee

Konkuk University

Journal of Biomedicine and Biotechnology

1110-7243 (ISSN) 1110-7251 (eISSN)

Vol. 2012 article ID 956345- 956345

Subject Categories

Industrial Biotechnology

DOI

10.1155/2012/956345

More information

Latest update

7/20/2021